Serkan Aslan is a Ph.D. candidate at the Division of Drug Discovery and Safety (DDS) since November 2022. I obtained my BSc degree from Bogazici University in Molecular Biology & Genetics, then had my MSc degree from Ludwig Maximilian University in Cellular & Molecular Biology with a specialization in stem cell biology. My Ph.D. project focuses on high throughput drug screening of human induced pluripotent stem cell-derived liver, kidney, and neuronal cells via high-content live cell imaging to discover new compounds that regulate the KEAP1-NRF2 oxidative stress response pathway. The cells will then be subjected to transcriptomic and metabolomic analysis on a single cell level to understand how regulation of the KEAP1-NRF2 pathway alters the transcriptome and the metabolome, their interaction with each other, and the variability among the different cell types.
No relevant ancillary activities